UBS maintained Johnson & Johnson (NYSE: JNJ ) at Buy with a $180 per share price target on Friday in its analyst day preview note.
The firm said it expects the company to reiterate its pharma guide, while its MedTech guide will at least be in line with market growth.
"Led by new management, the shift is underway to transition JNJ into a more innovative, higher growth, and nimble business," said analysts at UBS. "With the spinout of the Consumer franchise now in the rear-view mirror, focus falls on management's expectations on the rest of the business ahead of JNJ's Enterprise Business Review on December 5th."
UBS also anticipates JNJ management will give some commentary on its capital allocation strategy, as "the company highlighted key priorities following the August 30th guidance update post-Kenvue -- noting that organic growth business needs remain highest priority, with free cash flow generation another area of focus."
They also expect comments on the company's broader P&L targets and the financial profile of the new JNJ.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.